Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| By delivering fourth quarter results, including positive adjusted EBITDA, we should be well positioned to execute on our 2024 plans and achieve financial self-sustainability |
| Our differentiated technology, large installed base and recently launched HVT 2.0 product give us the opportunity to drive significant revenue growth |
| Our international business continues to successfully sell the Oxygen Assist Module for Precision Flow, and we expect it to be a major contributor of growth in our international business |
| We continue to execute well against our path to profitability initiatives and saw another sequential quarter, our sixth quarter in a row, of reduced non-GAAP cash operating expenses, lower inventory balances and reduced cash burn |
| The receptivity to our HVT 2.0 continues to be strong from a customer perspective |
| Overall, the transition to our Mexico operation has been incredibly smooth as evidenced by our consistent sequential improvement in gross margin for several quarters |
| The last three quarters of this year will be the first three quarters without the impact of COVID skewing the results and demonstrate the strong growth potential in our underlying business without incremental investments |
| Also, the combination of expected revenue growth, continued gross margin improvement and decreased cash OpEx positions us to become adjusted EBITDA positive in the fourth quarter of '23 and then cash flow positive in mid-2024 |
| I'm very proud of our execution on our path to profitability initiatives |
| The significant progress we've made in these key metrics, when combined with the additional actions we took in the third quarter of this year to further reduce our non-GAAP cash operating expenses, gives us confidence that we will become adjusted EBITDA positive in the fourth quarter of 2023 |
| Obviously, good to see cash burn continue to improve this quarter |
| As we look to close out the year strong, our focus will continue to be [indiscernible] towards profitability through revenue growth, gross margin improvement and driving cash operating expense below pre-IPO levels while investing prudently in future growth drivers, such as the home market and clinical studies |
| In conclusion, I'm pleased with the progress we've made on our path to profitability initiatives |
| We have consistently reduced our cash burn every quarter for the past six quarters through a combination of revenue growth, gross margin improvement and reduced cash operating expenses |
| We are not cash flow positive yet, but we've made incredible progress, and getting to adjusted EBITDA is the first step, which we expect to see this upcoming quarter |
| Very nice to see |
| This, along with further expected reductions in our inventory levels, should allow us to then turn cash flow positive in mid-2024, which means that we should have enough cash in our balance sheet to execute on our business plans without raising additional capital |
| Yes, we're pleased with the reduction in our cash burn this past quarter |
| Now that the underlying market has returned to more normal year-over-year comparability, the progress we're making on the top line is clear to see with growth in the high teens this quarter |
| We had a setback this quarter, but we believe that these onetime costs are behind us, our performance is back on track, and we expect to see significant gross margin improvement return in the fourth quarter of this year |
| We expect to increase worldwide disposables revenue by growing our HVT 2.0 installed base and our ongoing efforts to increase awareness of the effectiveness of our technology in treating acute hypercapnic respiratory failure in COPD patients as well as other long seasonal conditions requiring respiratory support |
| Worldwide capital and worldwide disposables revenue grew 25% and 18%, respectively, as compared to the third quarter of 2022 |
| Revenue, excluding revenue from the Vapotherm Access call center business, which we commercially exited in the fourth quarter of '22, grew 18% in the third quarter as compared to the third quarter of '22 |
| Very encouraging, John |
| And if we do that over the next three years, we can grow our business 15% plus per year just by getting back to those turn rates in our Gold account |
| We recorded an adjusted EBITDA loss of $6.1 million in the third quarter of 2023, which is $300,000 less than our adjusted EBITDA loss of $6.4 million in the second quarter of 2023 and significant improvement over our adjusted EBITDA loss of $17.7 million in the third quarter of 2022 |
| HVT 2.0, sounds like there continues to be strong demand for it, and it's certainly a big growth driver year-over-year |
| Through continued execution, we then expect to become cash flow positive in mid-2024 |
| In the U.S., customers continue to upgrade their installed base of Precision Flow units to HVT 2.0 units, given its ease of use and built-in air source, which allows it to be used throughout the hospital |
| High VNI is delivered via a mask-free interface, providing greater patient comfort and protecting the patient's ability to speak [indiscernible] |
| Statement |
|---|
| Gross margin was 39.6% in the third quarter, which is down from 42.8% in the second quarter of 2023 due to inefficiencies in our Mexico facility as we significantly ramp production in anticipation of RSV and flu season in the Northern Hemisphere |
| Gross margin in the third quarter decreased by 300 basis points from the second quarter of 2023 as we scaled our Mexico operation to run 24/7 for the first time in advance of the upcoming RSV and flu seasons |
| This is a deceleration from the third quarter primarily due to a tough comp in the fourth quarter of last year due to an unusually early flu season |
| Second, we have stopped our MODERATION Neo clinical trial, which was designed to support the safety of the Oxygen Assist Module on the Precision Flow platform in the U.S |
| Non-GAAP cash operating expenses were $12.3 million in the third quarter, down from $14.2 million in the second quarter of 2023 |
| Doing so, we incurred higher scrap rates and lower first pass yields as we work through the new higher learning curve of the additional shifts and incurred higher freight costs |
| But I noticed that it stepped down a decent amount sequentially |
| GAAP operating expenses were $16.3 million in the third quarter, down from $24.8 million in the third quarter of 2022 |
| While bi-level pressure systems are the current standard of care, many patients cannot tolerate the discomfort and complications associated with the mask required for those systems |
| Acute hypercapnia is a life-threatening condition in which a patient is unable to effectively remove excess carbon dioxide out of the body |
| So unusual pattern there |
| Our cash burn was $3.6 million this quarter |
| We're not losing deals |
| Non-GAAP cash operating expenses decreased from $19.5 million in the third quarter of 2022, a year-over-year reduction of $7.2 million or 37% |
| We continue to reduce our inventory levels and converted another $1.5 million of excess inventory into cash in the quarter |
Please consider a small donation if you think this website provides you with relevant information